Clinical Trials Directory

Trials / Completed

CompletedNCT01684098

Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor

A Phase II Clinical Study to Evaluate the Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
40 (planned)
Sponsor
Endocyte · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The folate receptor is over-expressed on many types of cancer cells and new folate receptor targeted therapies are being developed to target cancer cells that over-express the folate receptor. As with other targeted therapies, it is important to develop diagnostic tests that will provide accurate information on folate receptor status and aid in selecting patients that may benefit from folate-targeted therapy.

Detailed description

This Phase II, limited institution, open-label, single-arm, baseline-controlled study is designed to obtain data on the percentage of patients with recurrent or metastatic cancer from a solid tumor (including, but not limited to, breast, lung, mesothelioma, liver, colorectal, prostate, head and neck, pancreas, bladder and testicular cancer) with increased uptake of FalateScan in tumors, correlate the immunohistochemical staining findings with the FolateScan images, and verify product safety in patients with suspected recurrent or metastatic disease from any solid tumor.

Conditions

Interventions

TypeNameDescription
DRUGTc 99m EC20

Timeline

Start date
2003-08-01
Completion
2005-08-01
First posted
2012-09-12
Last updated
2023-06-22

Source: ClinicalTrials.gov record NCT01684098. Inclusion in this directory is not an endorsement.